Citigroup
ORIC icon

Citigroup’s Oric Pharmaceuticals ORIC Stock Holding History

Citigroup’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,700
Closed -$703K – 6325
2021
Q1 		$703K Buy
+28,700
New +$907K ﹤0.01% 3225

Other funds holding ORIC

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Citigroup's ORIC Position: Q3 2026 in Review

Citigroup reduced its Oric Pharmaceuticals (ORIC) stake by 25% in Q3 2026, selling an estimated $784K and leaving 185,763 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2643.

Citigroup first reported a position in ORIC in Q2 2020 and has held it in 25 quarters since. The position peaked at $2.69M in Q2 2026. 34 funds tracked by Wall St. Rank hold ORIC as of Q3 2026.

  • Citigroup held 185,763 shares of Oric Pharmaceuticals worth $2.5M as of Q3 2026.
  • Citigroup sold 62,994 Oric Pharmaceuticals shares in Q3 2026, an estimated $784K.
  • Oric Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2643 holding.
  • Citigroup first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Citigroup's Oric Pharmaceuticals position peaked at $2.69M in Q2 2026.
  • 34 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.